About: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 December 2011

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2011 (uk) article scientifique publié en 2011 (fr) scientific article published on 27 December 2011 (en) artículu científicu espublizáu n'avientu de 2011 (ast)
publication date	wds:Q83145997-C577EE51-9046-425D-B13E-AC7D7939B620
publication date	2011-12-27 00:00:00Z (xsd:dateTime)
author name string	wds:Q83145997-00BC2996-27FD-49A6-B2E7-932FA0253BA9 wds:Q83145997-367C60DD-4031-4E3E-95BE-E2868059B61D wds:Q83145997-58957EF4-9630-4DE2-9BEC-B5160FA10C4D wds:Q83145997-5F9AFC31-30F6-426A-80EF-F430E9673E57 wds:Q83145997-6F7AEFD5-CF69-4F52-873F-B911B63F721A wds:Q83145997-70AEF938-0B5D-4D42-B22C-D5E0B6879F05 wds:Q83145997-7CA76D7A-12C3-43F7-8C82-24EFA51DAA10 wds:Q83145997-99FC3106-19FA-4BC0-93AB-ACA64C1F366D wds:Q83145997-A2937D65-33CA-4450-A53B-9C4BC8A69F28 wds:Q83145997-D612E419-5C4D-483D-BFBD-9E56F3877BA0 wds:Q83145997-DCE5DB8C-8958-4DB3-94E6-6F06A37735F6 wds:Q83145997-E0C77414-6C54-41F3-BCC7-ACAF76363439 wds:Q83145997-FBFB9A91-E50D-46F5-B78D-66DCB77EB0DE
author name string	Michael Friedlander Beth Y Karlan Bella Kaufman Charlie Gourley Joo Ern Ang Stan B Kaye James Carmichael Lee-May Chen Tamar Safra Katherine M Bell-McGuinn Elizabeth S Lowe Mark Wickens Amit Amnon
rdfs:label	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (en) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (nl)
skos:prefLabel	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (en) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (nl)
name	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (en) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (nl)
author	wds:Q83145997-9641DD7B-1785-453A-A419-98130ACADF9B wds:Q83145997-A59F0D26-FA0F-4444-99FA-5B52F77E7A13 wds:Q83145997-E14992D0-6E20-4C74-82E8-6A8A8EB85C9E
author	Ignace Vergote Jan Lubiński Ursula A. Matulonis
title	wds:Q83145997-27EEFF28-134B-4022-83C2-25E08130BFB3
title	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (en)
page(s)	wds:Q83145997-6104A207-A550-4E5A-899D-0E3544ACF993
page(s)	372-379
instance of	wds:Q83145997-C3859064-A395-4AA2-9200-E69EF45475BB
instance of	scholarly article
main subject	wds:Q83145997-3CD142FD-3B82-4D9B-81D3-29D5866C9737 wds:Q83145997-EE442682-B9B5-49D5-9A08-F77DF1D01161 wds:Q83145997-EE871253-3FEC-4B81-805F-6482A26C1DDA
main subject	ovarian neoplasm wd:Q18936 wd:Q7083106
PubMed ID	wds:Q83145997-D54FEA2B-7873-43C2-B967-1C6957996F4B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22203755
PubMed ID	22203755
published in	wds:Q83145997-0A9B3DB7-F9F7-4D39-8363-749D78A87BA8
published in	Journal of Clinical Oncology
issue	wds:Q83145997-941CEF8D-1BAB-44DD-B6AF-BC415C8212DE
volume	wds:Q83145997-5FBC8498-D141-4B03-965D-B5673F17D00D
issue	4
volume	30
DOI	wds:Q83145997-5726D744-192D-4879-A105-831D9E6D073C
DOI	http://dx.doi.org/10.1200/JCO.2011.36.9215
DOI	10.1200/JCO.2011.36.9215
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q83145997
is cites work of	Ovarian cancer standard of care: are there real alternatives? PARP inhibitors in ovarian cancer: current status and future promise Targeting tumour-supportive cellular machineries in anticancer drug development A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. Predictive biomarkers for cancer therapy with PARP inhibitors. An update on PARP inhibitors--moving to the adjuvant setting Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis Olaparib: first global approval Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Primary extraosseous Ewing sarcoma of the lung in children Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? Major clinical research advances in gynecologic cancer in 2012. Latest research and treatment of advanced-stage epithelial ovarian cancer PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions PARP inhibitors: the race is on. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer Better therapeutic trials in ovarian cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software